Cardiovascular

It remains unclear whether measures of magnetic resonance imaging plaque characteristics are associated with cardiovascular disease events independent of plaque burden at the population level.

Finerenone may represent an important step forward to reducing cardiac illness and death in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), the study said.

The investigator of the STRENGTH study says findings raise questions about the landmark REDUCE-IT trial, but other evidence suggests the drugs involved are different.

Using Plan-Do-Study-Act cycles, the studied intervention reduced hospital inpatient telemetry time by 51.25% while increasing American Heart Association (AHA) guideline–based usage.

The authors report overutilization of telemetry monitoring in a community setting, increasing the cost of health care and potential harm to patients with unnecessary interventions.

Calculating a social score is feasible and it predicts cardiovascular outcomes. In order to do this, institutions have to collect social determinants of health.

Deepak L. Bhatt, MD, MPH, of Brigham and Women’s Hospital Heart & Vascular Center and Harvard Medical School, presented the latest round of data from REDUCE-IT at the American Society of Preventive Cardiology Virtual Summit 2020 this morning

Transient ischemic attack is a common form of stroke, and 1 in 4 stroke survivors go on to experience a second stroke—most within the first month.

A finding that ertugliflozin produced a 30% drop in heart failure hospitalization risk fell outside the study’s primary and secondary end points; here, the drug performed within range of its class, the sodium glucose co-transporter 2 (SGLT2) inhibitors.

Many in the endocrinology community still endorse using metformin first in patients with type 2 diabetes, but that isn’t really necessary any more now that sodium-glucose transport protein 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are available, said Darren K. McGuire, MD, MHSc, professor of medicine in the Division of Cardiology, Dallas Heart Ball Chair for Research on Heart Disease in Women, Distinguished Teaching Professor, at the University of Texas Southwestern Medical Center.

Yale's Silvio Inzucchi, MD, who has been involved in groundbreaking trials with SGLT2 inhibitors for the past decade, shared data that show patients who did not have type 2 diabetes (T2D) when they started the DAPA-HF trial were 32% less likely to develop the disease if they took dapagliflozin (Farxiga) instead of placebo.

When it comes to diabetes, lead study author Deepak L. Bhatt, MD, MPH, said clinicians and payers should weigh the considerable costs of what happens when a patient suffers a heart attack or stroke when deciding on a treatment regimen.

In a debate at the American Diabetes Association 80th Scientific Sessions, Darren K. McGuire, MD, MHSc, professor of medicine in the Division of Cardiology, Dallas Heart Ball Chair for Research on Heart Disease in Women, Distinguished Teaching Professor, at the University of Texas Southwestern Medical Center, will discuss whether sodium-glucose transport protein 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are ready to be used for primary cardiovascular prevention.